Today
  • 10:35

    in 2026, Bank Indonesia Plans to Roll Over 173.4 Trln Rupiah in Maturing Govt Bonds to New Bonds - Joint Statement From Cenbank, Govt

    09:32

    the Cannabist Company Further Extends Forbearance Agreement With Senior Noteholders

    09:29

    South Korea Industry Ministry: Consultation With U.S. on Trade Deal Implementation to Continue in Favourable Manner

    09:01

    AWS: Identified Root Cause of Connectivity Issues to US-East-1 Region, Actively Working to Mitigate Issue

    09:00

    Reminder: Beyond Meat, Inc. Investors With Significant Losses Must Act by March 24, 2026

    08:50

    Rakovina Therapeutics Announces Upsized Financing up to $2.0 Million

    08:42

    AWS: We Are Investigating Connectivity Loss Impacting AWS Direct Connect Connectivity to the US-East-1 Region

    08:26

    Westshore Terminals Announces $165 Million Credit Facility

    07:16

    Brazil's Copasa: BTG Pactual, Itau Bba, Bofa, Citi and UBS Bb Tapped as Bookrunners of Copasa's Potential Share Offering - Filing

    07:12

    Smartstop Self Storage REIT Announces Appointment of New Management Board Member

    07:05

    Txnm Energy Inc - Hart-Scott-Rodino Period for Acquisition Expired

    07:05

    Ferc Authorizes Txnm Energy Acquisition by Blackstone Infrastructure, Finds Transaction Consistent With Public Interest

    06:59

    Vanda Pharmaceuticals Inc: Includes Warning for Bysanti, Increased Mortality in Elderly Patients With Dementia-Related Psychosis

    06:59

    Vanda Pharmaceuticals Announces FDA Approval of Bysanti™ (Milsaperidone) for the Treatment of Bipolar I Disorder and Schizophrenia - a New Chemical Entity Opening New Horizons in Psychiatric Innovation

    06:59

    Vanda Pharmaceuticals Inc - Bysanti Expected to Be Commercially Available in Q3 2026

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10